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ABSTRACT Best supportive care (BSC) is generally defined as all the interventions and the
multiprofessional approach aimed to improve and optimise quality of life (QoL) in patients affected by
progressive diseases. In this sense, it excludes and might be complementary to other interventions directly
targeting the disease. BSC improves survival in patients with different types of cancer. Patients with
idiopathic pulmonary fibrosis (IPF) experience a vast range of symptoms during the natural history of the
disease and might have a beneficial effect of BSC interventions. This review highlights the current evidence
on interventions targeting QoL and gaps for the clinical assessment of BSC in the treatment of IPF
patients. Very few interventions to improve QoL or improve symptom control are currently supported by
well-designed studies. Sound methodology is paramount in evaluating BSC in IPF, as well as the use of
validated tools to measure QoL and symptom control in this specific group of patients.
Introduction
Idiopathic pulmonary fibrosis (IPF) is a progressive respiratory disease characterised by a scarring process of
the lung, bringing patients to respiratory failure and death in 3–5 years from diagnosis [1, 2]. New
antifibrotic treatments are able to reduce the loss of respiratory function over time [3, 4], but their effect on
symptom control and quality of life (QoL) is limited and needs further exploration [5–7]. A
multidisciplinary approach for the diagnosis and treatment of IPF is recommended by current guidelines [1],
as it has been shown to result in a more accurate diagnosis [8] and to positively affect survival in this group
of patients [9].
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Best supportive care (BSC) is generally defined as all the interventions and the multiprofessional approach
aimed to improve and to optimise QoL in patients affected by progressive diseases, taking into account
physical, psychosocial, spiritual and cultural needs. Therapies targeting the disease, such as chemotherapy
in cancer, are considered complementary but are not necessarily a part of BSC [10]. As such, it should be
clearly distinguished from end-of-life care, adopted to reduce emotional and physical suffering in patients
at the very last moments of their life, when active treatments and rehabilitation are no longer meaningful
for patients [11, 12].
Most of the evidence about the efficacy of BSC in progressive diseases is derived from oncology, where it is
recognised that BSC can influence survival [13]. Therefore, its role should be carefully considered when
designing multicentre randomised trials [14, 15]. Unfortunately, an internationally accepted definition of
BSC is not available, nor has it been possible to reach a consensus on a definition of BSC in oncology
trials, due to the fact that the types of intervention vary greatly among different diseases. Therefore, a
common definition of BSC and shared tools for its evaluation are simply not available [16]. Furthermore,
the quality of BSC depends on the availability of resources to allocate to such interventions, and local
differences play a major role in access to BSC.
Four domains are considered essential for the planning and evaluation of BSC strategies: multidisciplinary
care, supportive care documentation, symptom assessment and symptom management (figure 1) [16]. The
National Institute for Health and Care Excellence (UK) has identified BSC as a very important component
of the management of patients with IPF, and has identified 13 components (varying from an accurate
diagnosis to spiritual support) that should be addressed by caregivers, although no or very limited
evidence is available to support their role or effect in improving QoL in this group of patients [17].
Relatively simple questions, such as the role of long-term oxygen treatment, are still not systematically
explored with well-designed, targeted studies, so most of the recommendations in guidelines today are
based on expert opinion or experiences from other fields, such as chronic obstructive pulmonary disease
(COPD) and lung cancer [3]. In this review article, we will discuss what may be acknowledged as the state
of the art for BSC for patients with IPF, based on the four aforementioned domains, with special emphasis
on unanswered questions for future research.
Multidisciplinary care for patients with IPF
A multidisciplinary approach is strongly recommended by international guidelines on the diagnosis and
treatment of IPF. Multidisciplinary conferences have rapidly become the main way to ensure quality and
consistency in the diagnostic process, especially in university hospitals, and are recommended as the best
possible “gold standard” for diagnosis in difficult cases [1, 18]. Highly specialised centres for the diagnosis
and treatment of interstitial lung diseases (ILDs) have been developed and have been recommended by
expert panels for the UK National Health Service on the model of current cancer services [19].
There is, however, no clear definition of multidisciplinary care of IPF, and it is unclear which professions
should be involved in the care of this group of patients. Furthermore, the possibility to build a
multidisciplinary team is strictly dependent on local resources, so great variability can be expected across
the same healthcare system and especially among different countries and cultures/continents [20].
Although based on expert opinion with very few studies supporting this approach, it is recommended that
access to specialised healthcare professionals should be regulated via referrals from primary care to
specialists and thereafter to specialised centres [19]. At the tertiary level, a very important role is played by
nurses specialising in the care of patients with ILDs [21, 22]. Indeed, as the main patient contacts in the
healthcare system, they play a pivotal role in addressing a patient’s needs and in coordinating a
multidisciplinary team of other professionals around the patient. An example of the composition of such a
team is shown in figure 1. It includes specialists with expertise in the care of ILDs, physiotherapists,
occupational medicine professionals and professionals with expertise in the delivery of oxygen therapy,
while psychologists, medical counsellors and professionals with expertise in providing palliative care are
also very important for patients with progressive forms of ILDs. One of the main advantages of such
organisation is the possibility to optimise the flow of patients, minimising delays in access to treatments
and interventions, and at the same time giving a clear reference to patients, who often feel alone with their
disease [13].
A very important task of the multidisciplinary team is the coordination of all the procedures/interventions
to shortlist potential candidates for lung transplantation, thus avoiding unnecessary delays.
Supportive care documentation
A major problem is that BSC interventions are poorly reported, both in clinical trials and in real-life
patient cohorts [16]. As discussed, there is no consensus on what is generally considered supportive care,
and this is even less defined for rare diseases, such as ILDs in general and IPF in particular.
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Trials targeted to slow down the progression of the disease [5, 6] have not reported data on BSC, and QoL
was only a secondary outcome. Very poor attention has been paid to additional interventions (e.g.
nutritional support, cough management and psychological support), even in studies targeted to assess the
effect of new treatments or pulmonary rehabilitation on symptom control and the exercise capacity of IPF
patients [23, 24].
It is thus paramount to define which complementary interventions are considered BSC in IPF patients and
to implement specific ways of reporting how these interventions are used and their effect on the clinical
history of the patients, both in randomised controlled trials (RCTs) and in real-life cohorts. The time of
start, duration, intensity, follow-up and termination of an intervention should be documented with the
same accuracy as for treatment interventions in RCTs, and their potential detrimental effect should also be
carefully documented.
Symptom assessment
The major problem with the evaluation of QoL in IPF is that it has never been systematically and
rigorously explored. Most data are collected by so-called “big RCTs” on new treatments [5, 6], but there
are several limitations to this approach. First, exactly as in oncology, BSC interventions in control groups
have never been clearly defined, and most results on QoL have been targeted to describe the effect of the
intervention in the treatment arm in comparison to the control group. Secondly, most studies with
primary outcomes strictly related to QoL (e.g. studies on the effect of drugs for pulmonary hypertension
on dyspnoea and exercise capacity [23, 25–27]) have not shown positive results, and the duration of all
RCTs has always been limited and often powered on surrogate outcomes. Last, but not least, there is a
huge variability in the tools used to measure QoL in different studies, which often use questionnaires
validated for other diseases (and not for IPF) or adjusted with poor methodology to fit the scope of the
clinical trials.
Common tools to explore QoL are the EQ-5D (EuroQoL 5 dimension questionnaire) [28] and SF-36/
RAND (36-item Short-Form Health Survey, developed by RAND, Santa Monica, CA, USA) [29], and their
Multidisciplinary/interdisciplinary IPF team
Respiratory disease specialist
Other specialists  (thoracic radiologist, pathologist, rheumatologist, physiologist,
  immunologist, thoracic surgeon, pharmacologist)
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  interventions
Symptom assessment
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    interdisciplinary group, based on patient’s need
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  available evidence
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FIGURE 1 Flowchart showing the requirement for starting, documenting and evaluating the effect on quality of life (QoL) of interdisciplinary best
supportive care in patients with idiopathic pulmonary fibrosis (IPF).
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use is encouraged by regulatory authorities when collecting data for national quality registries [30].
Unfortunately, they were developed to measure QoL in diseases with high prevalence in the population,
and to explore domains (like physical pain) not really of primary interest when treating IPF and ILDs.
Recently, there has been a shift in assessing QoL in IPF and other fibrotic disorders. New tools offer a
detailed assessment of major symptoms such breathlessness, but, unlike breathlessness scales, they also
assess the impact of symptoms on activities, social interactions and mental health. The most widely used
tool to assess QoL has been the St George’s Respiratory Questionnaire (SGRQ) [31]. The validity of the
SGRQ in IPF has been evaluated and is good [32]. When assessed with the SGRQ, QoL is severely
impaired in IPF and comparable to other chronic disorders such as COPD [32, 33]. Although the SGRQ
has been useful for gaining an early insight into the QoL of patients with IPF since it became readily
available, it has some drawbacks. First, it was developed for COPD and not for IPF; as a consequence, it
contains items that are not relevant to IPF. This potentially has a negative impact on the responsiveness of
a tool, i.e. the ability to detect change. The SGRQ is also lengthy, containing 50 items. Recently, YORKE
et al. [34] conducted a study to reduce the SGRQ to 34 items using well-established psychometric
methodologies such as Rasch analysis. The SGRQ-IPF has good validity. It has, however, not been used
widely, perhaps because of its length or because the initial pool of questions used to construct the
questionnaire were for COPD and not IPF patients, so concerns regarding disease specificity remain.
SWIGRIS et al. [35] have developed an IPF-specific questionnaire (A Tool to Assess Quality of Life in IPF
(ATAQ-IPF)) using validated methods. The ATAQ-IPF has good validity characteristics. The main
limitation of the ATAQ-IPF is its length; 75 items are too many to be practical for routine clinical use or
in clinical trials. Recently, YORKE et al. [36] have significantly reduced the number of items to 43, while
retaining its validity in a USA–UK version called the cross-Atlantic ATAQ-IPF. The most recent QoL tool
developed for IPF is the King’s Brief Interstitial Lung Disease (K-BILD) questionnaire, which is composed
of 15 questions exploring three domains (psychological, breathlessness and activity, chest symptoms),
developed with modern item response theory methods, such as Rasch analysis [37]. The K-BILD has been
well validated and its performance in fibrosing lung disorders has been as good as that in IPF [38, 39]. An
advantage of the K-BILD is that it is brief and therefore practical. Its limitation is that it is relatively new
and therefore few studies reporting its use are available. It also does not include any item to evaluate
cough. Cough items were removed by Rasch analysis during development, because they did not conform
to a unidimensional scale. This may have been because, while cough is a common symptom, the
prevalence of severe and bothersome cough in IPF is poorly characterised and reported, due to different
the methodologies and definitions used in the available studies [40]. Tools for the assessment of common
symptoms (e.g. the Leicester Cough Questionnaire [41] or the modified Medical Research Council
dyspnoea score (mMRC) [42]) have been developed and validated for other medical conditions (mainly
COPD, refractory chronic cough) and only a few studies have been performed to assess their validity in
patients with IPF/ILDs [43, 44].
Furthermore, it must be considered that all the available tools require time for the patient and caregivers
to fill in the questionnaires and for evaluation of the results. Digital solutions offer the possibility to
simplify this process by sending the questionnaires via email or by completion on a tablet in the waiting
room before clinical evaluation [45].
Symptom management
Cough and exertional dyspnoea are the main symptoms reported by patients with IPF, with onset
2–5 years before diagnosis [1, 40]. In this section we will describe the main data on symptom control
for the main medical problems in IPF patients, with special consideration of the effect of intervention
on QoL. Table 1 offers an overview of the most common symptoms, tools and interventions to improve
QoL in IPF patients.
Dyspnoea and exercise capacity
Shortness of breath is one of the main symptoms affecting QoL in patients with IPF [48], presenting more
often as effort dyspnoea at the time of diagnosis, worsening during the natural history of the disease, until
being manifest at rest in the terminal phases [2]. So far, no intervention has been proved to reverse the
natural history of the disease and therefore to improve shortness of breath, acting on the causative
mechanisms of the disease. Antifibrotic therapies such as pirfenidone and nintedanib have not shown any
effect on dyspnoea, nor was this a primary outcome of published RCTs [5, 6]. Common interventions
used in clinical practice to reduce shortness of breath include treatment of comorbidities, physical
rehabilitation, supplemental oxygen and opioids/benzodiazepines [49].
Sildenafil has improved dyspnoea and QoL in a subgroup of IPF patients with pulmonary hypertension
[23, 50] and, although it is currently not recommended as a treatment for IPF by international guidelines,
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its use can be considered in patients with concomitant pulmonary hypertension and low diffusing capacity
for carbon monoxide, to improve effort dyspnoea and QoL [4]. No studies are available on the role of
bronchodilators in patients with IPF and signs of airflow obstruction at spirometry.
Physical rehabilitation can improve exercise tolerance, dyspnoea and QoL in patients with ILDs [24], and
its effect is proven in patients with IPF [51–53]. Despite differences in the programmes, outcomes and
scales used in the available studies and the open questions about the long-term effect of the intervention
and on how to maximise its effect [54], physical rehabilitation is probably the safest and most effective
treatment of dyspnoea, and is widely recommended for all patients with IPF [1].
The use of supplemental oxygen during exertion to relieve dyspnoea in patients who are normoxic at rest
but desaturating with exercise is still controversial: a recent meta-analysis, including 98 patients with IPF,
failed to show any evidence to support or refuse the use of supplemental oxygen on exertion [55]. A
recent study has shown that oxygen at a fraction of inspired oxygen of 0.50 improved tolerance, saturation
and dyspnoea during exercise in patients with IPF [56], and it is possible that differences in methodology,
oxygen dose and outcomes are behind the current uncertainty about this intervention and further studies
are needed to clarify its impact on health and QoL of patients with IPF.
Opioids are often used in the latest stages of the disease to reduce refractory dyspnoea and, as such, their
use should not really be contemplated for BSC. Their safety up to a dose of 30 mg·day−1 is based mainly
on data from other chronic respiratory diseases [57]. A recent systematic review showed some effect on
dyspnoea and exercise tolerance of systemic opioids in patients with IPF, but no effect at all of inhaled
morphine, and constipation was a significant adverse event [58]. A recent systematic review/meta-analysis
on the role of benzodiazepines for improving dyspnoea in patients with chronic respiratory diseases
(including IPF) showed that this class of drugs could have a better tolerability profile compared to
morphine, but not a better clinical effect [59]. Further studies are needed to better assess the value of
TABLE 1 Assessment and management of the most frequent problems in the best supportive care of patients with idiopathic
pulmonary fibrosis (IPF)
Symptom/factors limiting QoL Tool for assessment Interventions
General well-being EQ-5D
SF-36/RAND
SGRQ-IPF#
K-BILD#
ATAQ-IPF#
Management of symptoms influencing QoL
Mindfulness/meditation
Physical rehabilitation¶
Nutritional support
Dyspnoea mMRC
SGRQ-IPF#
K-BILD#
ATAQ-IPF-cA#
UCSD SOB#
Physical rehabilitation¶
Supplemental oxygen
Treatment of PH with sildenafil¶
Pharmacological interventions (morphine/benzodiazepines)¶
Cough LCQ#
VAS#
CQLQ#
Poor effect of usual anti-tussive drugs
Systemic steroids
Thalidomide¶
Gabapentin
Opiates
PSALTI
Anxiety/depression EQ-5D
SF-36/RAND
K-BILD#
SGRQ-IPF#
ATAQ-IPF-cA#
Counselling/cognitive behavioural therapy
Antidepressants
Physical rehabilitation
Nutritional support (loss of appetite)
Weight loss NA Nutritional support
Comorbidities NA Treatment of PH with sildenafil¶
Anti-reflux measures in patients with GORD
QoL: quality of life; EQ-5D: EuroQoL 5 dimension questionnaire [28]; SF-36/RAND: 36-item Short-Form Health Survey, developed by RAND
(Santa Monica, CA, USA) [29]; SGRQ-IPF: St George’s Respiratory Questionnaire, IPF-specific version [34]; K-BILD: King’s Brief Interstitial Lung
Disease questionnaire [38]; ATAQ-IPF: A Tool to Assess Quality of Life in IPF [35]; mMRC: modified Medical Research Council Dyspnoea
Questionnaire [42]; ATAQ-IPF-cA: cross-Atlantic ATAQ-IPF [36]; UCSD SOB: University California San Diego Shortness of Breath Questionnaire
[46]; LCQ: Leicester Cough Questionnaire [41]; VAS: visual analogue scale cough [47]; CQLQ: Cough Quality-of-Life Questionnaire; NA: not
applicable; PH: pulmonary hypertension; PSALTI: physiotherapy, and speech and language intervention; GORD: gastro-oesophageal reflux
disease. #: validated for use in IPF patients; ¶: efficacy somehow proved by randomised controlled trials involving patients with IPF.
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opioids and benzodiazepines in the treatment of dyspnoea in IPF patients, but side-effects such as
drowsiness seem to reduce their clinical utility in patients at an early disease stage.
Cough
One symptom with a marked impact on daily life in IPF patients is cough [40]. It is usually refractory and
considered an independent predictor of disease progression [60]. In the majority of patients, cough is
among the first symptoms, often preceding dyspnoea on exertion, sometimes by years [61]. Cough in IPF
patients is more common during the day and rarely wakens the patients from sleep, consistent with the
diurnal variation reported in many chronic respiratory disorders [62]. Cough may coexist or be
exacerbated by comorbid illnesses such as gastro-oesophageal reflux, despite its treatment [63], and is
generally refractory to medical therapy [48]. In fact, symptomatic anti-tussive treatment is usually not
effective [64].
Oral corticosteroids have been shown to be effective in improving cough in some IPF patients [64], and
low doses of prednisone are sometimes prescribed in daily practice for this purpose and are then slowly
tapered if they are beneficial [40]. However, no effect on QoL and survival has been shown, and possible
side-effects should be taken into consideration [40]. Although opiates are recommended in palliative care,
their effect has not been demonstrated in IPF [1]. Furthermore, administration of opiates might be
effective for palliation of severe cough in patients with advanced IPF.
HORTON et al. [65] studied the efficacy of thalidomide in suppressing cough in IPF patients. Using the
Cough Quality-of-Life Questionnaire [66], they showed that thalidomide significantly improved cough in
IPF patients. However, adverse events (mainly constipation, dizziness and malaise) occurred with high
prevalence in patients receiving thalidomide. Evaluating the need to calculate a cost-effective benefit in
administering thalidomide, only 20% of the screened subjects completed the study, with potentially severe
side-effects. The mechanism of action of thalidomide is not known but is thought to be anti-inflammatory.
Its side-effect profile, including dizziness and neuropathy, suggests that it might also have effects on
sensory nerves, potentially explaining the effect of thalidomide on chronic cough. Although these results
suggest the need for further investigations, thalidomide should not be considered a routine treatment for
cough in IPF patients.
Although there are no specific trials performed in IPF, a meta-analysis focusing also on gabapentin has
shown promising results in relieving sensory neuropathic cough and therefore in the treatment of cough
for select cases of refractory chronic cough [67].
Mild to moderate IPF patients are usually treated with one of the two new antifibrotic drugs, pirfenidone
or nintedanib [3]. Although the impact of these drugs on cough has not been extensively studied, there are
some indications of a potential effect. Some effect has been shown, at least for pirfenidone, both in animal
models [68] and in humans [69]. Currently, no data are available on the effect of nintedanib on cough,
and the recommendation of these drugs in the guidelines concerns only their effect on lung function [3].
Recently, an RCT showed the efficacy of a combination of nonpharmacological interventions, grouped
under the term “physiotherapy, and speech and language intervention” (PSALTI), in patients with
refractory chronic cough [70]; this approach remains to be proven in IPF, but highlights the potential
benefit of physiotherapy and nonpharmacological interventions.
Anxiety/depression and weight loss
IPF is a chronic condition with significant morbidity and mortality and, as with other chronic diseases, is
frequently associated with anxiety and depression. Anxiety and depression are known to occur frequently in
patients with dyspnoea [71, 72]. In COPD, reported breathlessness severity is linked both with depression
and functional impairment [73]. Qualitative studies in COPD reported the patient-described perception of
acute dyspnoea as “an experience inextricably related to anxiety and emotional functioning” [74].
Depression and anxiety should not be considered unrelated to breathlessness, or cough and other
symptom increase, and require particular attention in IPF patients. Clinically significant symptoms of
depression and anxiety are present in up to 50% and 30% of IPF patients [75–77], respectively, as well as
in COPD, and are associated with dyspnoea and disease severity [78]. The presence of these symptoms
deeply affects IPF patients’ QoL [78]. All patients with IPF should be investigated regarding these
symptoms at the time of diagnosis and when disease progresses and becomes severe [79, 80]. The close
relationship between depression and anxiety and IPF severity suggests that these symptoms may improve
with treatment of the IPF itself, such as with antifibrotic treatments, supplemental oxygen and pulmonary
rehabilitation [79–81]. There are few data about the treatment results of clinically significant depression in
IPF patients (there are more data for COPD, and most treatment recommendations are extrapolated from
studies of non-IPF patients) [82, 83], but symptom persistence suggests that antidepressant and cognitive
behavioural therapy should not be delayed in order to improve QoL [84]. Pulmonary rehabilitation may be
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a useful treatment to improve psychological health in IPF through improvements in dyspnoea, fatigue and
exercise tolerance [79]. Poor appetite is a common symptom of depression, and this is one of the possible
causes of the weight loss observed in many people with severe IPF. Right heart failure, medications used
for cough control, increased energy consumption due to increased work of breathing, and “difficulty” in
eating can all contribute to weight loss. Lastly, the two drugs approved for IPF treatment, pirfenidone and
nintedanib, may cause nausea [5, 6], reduction of appetite and contribute to weight loss. Nutrition is one
of the less investigated aspects and unmet needs in IPF.
Treatment of comorbidities
As in many elderly populations, comorbid conditions are frequent in patients with IPF, affecting symptom
burden and perhaps prognosis [80]. Many comorbidities have been stated to be more common in IPF
than in the general population, including cardiovascular and thromboembolic diseases, depression, reflux
disease, emphysema, lung cancer, sleep disorders and diabetes [85]. Furthermore, a significant association
between the frequency of comorbidities and impaired health-related QoL has been described recently [86].
One may thus hypothesise that active screening for and treatment of comorbid conditions may ameliorate
the burden of disease, increase QoL and perhaps improve the prognosis in IPF. However, this is currently
under debate and has yet to be established. One example in this debate is gastro-oesophageal reflux
disease, which has been reported to be frequent in IPF patients and affects symptom burden [87]. This has
led to a discussion of a potential treatment effect of antireflux measures against IPF. Post hoc and
retrospective data that reported on positive effects of antacid therapies with regard to lung function decline
and acute exacerbations [88, 89] have led to a conditional recommendation for the use of antacid drugs in
all IPF patients [3]. However, more recent data could not support these findings and even hypothesised a
higher pulmonary infection rate in patients taking antacid drugs [90–92]. Therefore, future research must
aim to prospectively assess the impact of comorbidities on symptoms and outcome as well as respective
treatment measures. Currently, comorbidities in IPF should be treated as in non-IPF patients.
Conclusions
This review has explored the role of BSC in the clinical management of patients with IPF. As for other
fields, like oncology, defining BSC for ILDs and IPF is particularly difficult due to differences in the
methodologies of studies, scales to measure QoL and symptoms, and very often because BSC interventions
and their results are not or are only poorly documented, in both real life and RCTs.
A systematic approach, based on four pillars (multidisciplinary care, supportive care documentation,
symptom assessment and symptom management) [16] seems to offer the best framework to organise the
available published data and to address gaps and needs for further clinical research.
The multidisciplinary/interdisciplinary workup around IPF patients is paramount to address the complex
and multidimensional assessment of patients’ needs. As discussed in the introductory section, it has not
been demonstrated that this approach results in improved survival or QoL for IPF patients; nevertheless,
experts recommend this approach for IPF patients in tertiary reference centres for ILDs, mainly based on
the experience derived from cancer and other progressive diseases [19]. A very important task for the
multidisciplinary/interdisciplinary teams will be to show how this approach is beneficial for IPF patients
and eventually to explore the possibility of delegating some of its components to healthcare players in the
field. One example of a multidisciplinary/interdisciplinary team is the Outpatient Clinic for IPF at the
New Karolinska University Hospital in Stockholm, Sweden, where three respiratory disease specialists, two
specialised nurses, two physiotherapists, one dietician, one occupational medicine therapist, one medical
counsellor, two research nurses and a secretary work together to address all the supportive interventions
needed to optimise the condition of the patients. QoL is evaluated at every medical visit thanks to digital
solutions where the patient fills in QoL questionnaires on a tablet and scores are directly available to the
team. In addition, three radiologists, one pathologist and one physiologist work closely with the team,
taking regular part in monthly multidisciplinary conferences. The costs of this approach are high, and
policies and guidelines recommend it only in tertiary, specialised reference centres [19], where patients
with relatively rare diseases should be referred.
Documentation and analysis of the results of supportive interventions are also crucial to fill current gaps.
Digital solutions are slowly entering clinical practice and their implementation can enable patients to
self-report QoL and symptom scale measurements without absorbing resources from the staff. Simplified,
validated disease-specific questionnaires will also contribute to simplifying this task in the near future, but
at present it is important to devote time and resources to quality data reporting and analysis: this is crucial
to evaluate and improve the impact of supportive care strategies.
The effect of pharmacological and nonpharmacological interventions must be systematically documented
and evaluated in both clinical trials and real life (e.g. with a quality registry for IPF). This will contribute
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to improving evidence about the use of these interventions in the treatment of patients with IPF and other
ILDs and will contribute to highlighting areas of uncertainty and new research questions. It is thus very
important that BSC is taken into account when designing new trials and in real-life studies.
As discussed in the section on symptom management, very few BSC interventions are supported by
well-designed RCTs, so most approaches are based on experience and tradition at a single reference centre.
The authors of this review believe that more attention should be devoted to symptom control and QoL of
patients with IPF and that the current lack of studies on BSC should not limit the access of patients to
potentially beneficial interventions.
Physical rehabilitation has documented positive effects on general well-being and dyspnoea [51–53]. A
precise assessment of the symptoms should be offered to all IPF patients and should be performed by an
experienced physiotherapist with a 6-min walk test (6MWT) and validated tools; the same tools should be
used to document the effect of rehabilitation. Although the available studies are not conclusive on its effect
[55, 56], supplemental oxygen can be beneficial in patients showing desaturation during the 6MWT; this
need should be carefully assessed by a registered nurse with good experience in oxygen therapy,
performing a 6MWT without and with oxygen, registering arterial oxygen saturation (SaO2) and intensity
of dyspnoea during effort and trying to titrate the oxygen flow to maintain the SaO2 over 92%. Severe
cough can be an important clinical problem in patients with IPF. A combined approach with
pharmacological (including gabapentin [67] or thalidomide [65] in the severest cases) and
nonpharmacological (e.g. mucus mobilisation/physical rehabilitation or PSALTI [70]) interventions is
preferred in patients with severe cough, due to the limited effect of common anti-tussive drugs. Again, it is
paramount that experienced staff performs a precise assessment of the symptom and of the effect of the
interventions with validated tools. We do recommend nutritional support in patients reporting weight loss
and poor appetite, with assessment and follow-up performed by a dedicated dietician. In our experience,
psychological support is also very important to support IPF patients during their journey: a psychologist is
of great added value in the interdisciplinary team and the possibility to establish contact with such an
individual should be offered to all patients, at diagnosis and later on during the course of the disease.
Patients also appreciate the possibility to meet and discuss their disease with other patients and in
information meetings with all the professionals involved: such initiatives should be encouraged. Finally,
pharmacological treatment of anxiety/depression has to be considered as soon as such problems arise.
Optimal treatment of comorbidities is also important, as they can result in additional symptoms and
added short- and long-term complications.
Despite all the methodological and practical limitations and despite the lack of solid evidence on the
efficacy of the available interventions, a systematic collection of QoL measurements with validated tools
and large cohorts is urgently needed to obtain reliable data and to evaluate the potential impact of all the
available interventions on patient life.
National registries are a potential source of long-term, real-life data on QoL; the development and
validation of patient-reported outcome measures is considered one of the main goals for quality registries,
to ease resource allocation in the framework of value-based healthcare [30]. Although the same
methodological problems are present with real-life data, national registries are already implementing the
measurement of QoL in patients with IPF [45, 86, 93–95], and this approach will allow the collection of
prospective data on the clinical history of the disease and will offer the possibility to explore the long-term
effect of several interventions on QoL. One example is the recent report on QoL in the German
INSIGHTS-IPF registry [86]. Statistically significant associations of QoL with clinical symptoms,
number of comorbidities, hospitalisation rate and disease severity (including functional data) have
been reported [86]. The life of a patient with IPF is influenced by respiratory (dyspnoea, cough,
limited exercise capacity) and systemic (weight loss, anxiety/depression) symptoms/conditions [80] that
must be properly recorded and evaluated over time to assess the effect of different interventions on
their severity and impact on QoL. Furthermore, the role of comorbidities and of their respective
treatments must be taken into account and properly evaluated, as they influence QoL and prognosis in IPF
patients [80, 96, 97].
New clinical trials will need to precisely record all BSC interventions and measure QoL with appropriate
tools. The potential confounding factor of side-effects will be of relevance, especially in the case of
combination therapy [98, 99], and it is likely that supportive interventions will have a major role in
increasing tolerance to new treatments.
Our review highlights the need for a wider consensus to standardise definitions and methodologies about
BSC in IPF. We hope that this review will raise awareness for this important issue and boost the discussion
for inclusion of BSC as an important part of the clinical management of IPF patients.
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